Birds's Eye
Technicals
MovingAverage
Candlestick
PivotPoint
Fin Statements
Beta&Vols
Tech ChartsFundamental Analysis of Marksans Pharma - Growth / Value Index
MARKSANS - Valuation Highlights
Valuation Analysis
Book Value in last 3 years is trending up
Tsr Value Index - Poor Score of 34.72
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|---|
| Price to Earning | 22.64 | 32.15 | 46.46 % | ||
| Price to Book | 3.21 | 4.88 | 46.46 % | 3.01 | |
| Price to Sales | 2.91 | 4.63 | 46.46 % | ||
| Enterprise Value to EBITDA Multiple | 18.95 | 53.96 % |
MARKSANS - Profitability Highlights
Profitability Analysis
Piotroski F Score - Stable Value of 5.0
Annual Net Profit in last 3 years is trending up
EBITDA is continuously increasing for last 3 Years
Steady ROE in range of 15 to 20 for last 3 years
Steady Growth in EPS for last four quarters
Good Return On Capital Employed of 15.04
Good Return on Equity of 14.31% is achieved by the company
Good Net Margin of 12.85% is achieved by the company
Very Low Dividend Yield of 0 %
Low Earning Yield of 4.45 %
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|---|
| Return On Equity | 14.31 | 15.19 | 0 % | 4.21 | |
| Return On Asset | 11.07 | 11.70 | 0 % | 3.29 | |
| Net Profit Margin | 12.85 | 14.41 | 0 % | 15.00 | |
| Operating Profit Margin | 17.99 | 17.14 | 0 % | 21.31 | |
| EBITDA Margin | 21.17 | 23.38 | 0 % | 23.91 |
Highlights
| Market Cap | 81651.04 M |
| Enterprise Value | 77278.95 M |
| Price/Book TTM | 3.21 |
| Outstanding Share | 453163 K |
| Float/ Outstanding Share | 47.29% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 1.99 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 5.00 |
| Altman Z Score | 10.86 |
| Sloan Ratio | 0.084 |
| Peter Lynch Fair Value | 174.60 |
MARKSANS - Growth Highlights
Growth Analysis
Annual sales of the company is increased for three years in a row
Quarterly sales in last 5 years is trending up
Steady increase in Total Assets for last 3 Years
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 2803.29 (Cr) | 0 % | 4.72 % |
| Gross Profit | 1591.44 (Cr) | 91.75 % | 6.41 % |
| EBITDA | 593.58 (Cr) | 0 % | 9.21 % |
| Net Profit | 360.32 (Cr) | 0 % | 15.22 % |
| EPS | 7.96 | 0 % | NA |
MARKSANS - Stability Highlights
Stability Analysis
Tsr Stability Index - Excellent Score of 90.62
Altman Z Score of 10.81 suggests good Stability
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|
| Debt to Equity Ratio | 0.0284 | 8.39 % | 0.0245 | |
| Cash Ratio | 1.73 | -3.85 % | ||
| Quick Ratio | 3.19 | 0 % | 3.08 | |
| Shareholders Equity | 77.03 | 0 % | ||
| Debt to EBITDA | 0.115 | 8.39 % |
Historical Valuation Ratios of Marksans Pharma
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Marksans Pharma
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Marksans Pharma
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Marksans Pharma
Historical Solvency Ratios
Loading ...